Thelansis

 Marginal zone lymphoma (MZL) is the 3rd most common lymphoma, accounting for 8%–12% of all B-cell non-Hodgkin’s lymphomas (NHL). It is the second most common indolent non-Hodgkin’s lymphoma (iNHL) are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. At the time of presentation, most SMZL patients are asymptomatic, with anaemia, thrombocytopenia, or lymphocytosis discovered incidentally on routine blood tests. The development of MZL is associated with chronic antigen-mediated B-cell receptor (BCR) activation in most cases. Treatment for relapsed/refractory MZL is based on a patient’s age, overall health, symptoms, and the duration of remission from the last treatment they received. ·        The age-standardized incidence rate for MZL is 27.6 per million population in the USA. The cases are slightly higher in males than females (19.1). EMZ...